( A $20-million deal announced today to l...)Stem Cell Licensing Deal Positions Toronto as World Leader in Technology,Health

A $20-million deal announced today to license Canadian stem cell technology in the U.S. underscores the Toronto areas global leadership in stem cell research .

Under the agreement, Tissue Regeneration Therapeutics Inc. (TRT), an emerging Canadian life sciences company, will exclusively license its human umbilical cord perivascular cell (HUCPVC) technology to Stem Cell Authority Ltd. for family stem cell banking in the U.S. The licensing fees and annual minimum royalties will exceed $20-million (Cdn) over the next four years. The technology originated at the University of Toronto and has been offered to the public in Canada since March 2007 through a licensing agreement between TRT and Toronto-based CReAte Cord Blood Bank (CCBB).

Toronto is the first place in the world to bank perivascular mesenchymal stem cells from the human umbilical cord and we are extremely pleased to now be able to provide this opportunity to parents across the U.S., says Professor John E. Davies at U of Ts Institute of Biomaterials and Biomedical Engineering, senior inventor of the technology. This is a great example of how a university can facilitate the translation of professorial research from the university laboratory to commercial reality for the benefit of the public.

Currently, TRT technology is available to the Canadian public through CCBB, which markets HUCPVCs as Peristem. Once the baby is born, a health professional simply collects the cord tissue and places it in a bio-container supplied with a nutrient solution and then ships it to the CReATe laboratories for processing and storage. A technician at the laboratory uses a proprietary process to remove the cells from the cord tissue and stores them for future use. Unlike cord blood stem cells, which can also be harvested, mesenchymal cells are the building blocks for the muscle, bone and connective tissues of the body. HUCPVCs also serve as regulators of the immune system. Published uses of
'"/>




Page: 1 2
Related medicine news :

1. Ranbaxy Signs Licensing, Supply Agreement for Canadian Market
2. Merck Announces Plans for Licensing Atripla Widely in Developing World
3. PSivida, Pfizer Ink $165 Million Licensing Pact
4. Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt
5. Two New Anesthesia Positions Promise to Ease Surgery Queue
6. Avoid travel to Toronto - WHO
7. WHO Says Toronto Going Back on SARS-Affected List
8. Mysterious viral outbreak in Toronto, influenza ruled out
9. Satellite Clinic To Be Set Up in Toronto By Ohio-Based Cleveland Clinic
10. IOF World Congress On Osteoporosis To Be Held In Toronto
11. Hepatitis Scare in Toronto